MAISA (@MaisaCorp) header
MAISA (@MaisaCorp) profile picture

MAISA's Platform is based MAISA's proprietary Optimization on Mathematical Probability Algorithm (OMPA) which derived majority from applied mathematics.

U.S.A
Joined April 2013
Photo by MAISA (@MaisaCorp)Photo by MAISA (@MaisaCorp)Photo by MAISA (@MaisaCorp)Photo by MAISA (@MaisaCorp)Photo by MAISA (@MaisaCorp)Photo by MAISA (@MaisaCorp)Photo by MAISA (@MaisaCorp)Photo by MAISA (@MaisaCorp)Photo by MAISA (@MaisaCorp)Photo by MAISA (@MaisaCorp)
$SNDK Sandisk's previously announced 8-for-1 forward stock split took effect following Thursday's market close, with eligible shareholders receiving seven additional shares for each share they owned.
100
Costco Wholesale Corporation $COST $COST 1,107.74 +13.92 (+1.27%) Costco announced a $30-per-share special dividend, payable December 4 to shareholders of record November 24 $COST past special dividends 2023: $15/sh 2020: $10/sh Annual Yield Dividends: 0.53% | $5.85/sh/year
100
The S&P 500 is falling about 2% and the Nasdaq Composite (^IXIC) about 3.5%, enough to wipe out the Nasdaq's gain for 2026.
93
Chips are crashing like it's 2008 as the Nasdaq 100 nears a bear market
102
$ANVS FDA agrees with plan to pool safety data from four Alzheimer's and Parkinson's studies and to integrate it at the level of standardized analysis datasets Safety package will be built in parallel with ongoing studies; NDA submission planned after DUET-AD data readout
95
$SVRA The review of the BLA is ongoing and no revised action date has been provided by the agency.
131
$SVRA the US Food and Drug Administration communicated that it will not meet the target action date of the company's biologics license application for molgramostim inhalation solution, which is intended for autoimmune pulmonary alveolar proteinosis, a rare lung disorder.
141
$BLTE said the US Food and Drug Administration has extended its review of the marketing application for its experimental drug tinlarebant, which is being developed to treat Stargardt disease type 1, by three months
98
$SLS Underwriting Agreement, the Company granted the Underwriters a 30-day option to purchase up to 1,730,769 additional shares of Common Stock on the same terms as the Offering Shares The Company expects to receive net proceeds from the offering of approximately $161.8M
2
286
$NXAT because the Company effected a 1-for-30 reverse stock split on August 3, 2026, it is not eligible for the customary 180-calendar-day compliance period
217
Vivid Seats $SEAT announced a debt deal in a regulatory filing Thursday The lenders would provide $66 million in new first-lien, first-out term loans and receive 80% of $SEAT Class A common stock, and existing shareholders would retain a 20% stake
155
Blackstone $BX and Carlyle Group $CG are among a group of lenders that will take over Vivid Seats $SEAT in a deal that could reduce the online ticket marketplace's net debt by more than $200 million $SEAT Pre-market 2.00 -0.09(-4.31%)
144
Wells Fargo $WFC stood out among the 19 wirehouses and brokerage platforms Galaxy tracks. Its holdings rose by 14,636 BTC to 30,553, nearly doubling from 15,931 at the end of June.
128
Artificial intelligence has sped up early-stage drug development work at some of the world's largest pharmaceutical companies this year, cutting by as much as half the time it takes to produce new molecules and move them into the clinic
110
Markets are pricing in a 98.4% chance of an interest rate hike from the central bank at its next meeting in December 2026
117
Tango Therapeutics $TNGX plans to disclose lung cancer data for vopimetostat in January 2027.
187
Crescent Biopharma $CBIO expects proof-of-concept data for its PD-1xVEGF bispecific CR-001 in the first quarter of 2027
139
Cullinan Therapeutics $CGEM and partner Taiho Oncology are awaiting an FDA decision on zipalertinib, with a target action date of February 27, 2027.
153
$ANNX ARCHER II completion, including Month 24 analyses, is expected in the third quarter of 2027. If the DMC recommends that the endpoint has been met, the DMC will evaluate the two pre-specified sub-studies, with results anticipated in the first quarter of 2027.
222
$ANNX Tanruprubart U.S./EU FORWARD Data in GBS Strengthens BLA Submission Package Anticipated in Q4 2026; Tanruprubart EU MAA Currently Under Review An independent Data Monitoring Committee will assess the ARCHER II single study Month 15 primary endpoint in 4thQ2026
197